In a news release from the AHA, the ROCKET trial randomized patients with non-valvular Afib to warfarin or rivaroxaban (oral Xa inhibitor). The rate of stroke/emboli was significantly lower in the rivaroxaban group (1.7 vs 2.2 per 100 patient years), with no difference in rates of major bleeding. Rivaroxaban (an oral Xa inhibitor) and Dabigatran (an oral thrombin inhibitor) have both been proven to be at least as effective and safe as warfarin in reducing afib-related stroke (AHA site)
Share This Post
Categories
Related Posts
While all of us see patients who smoke in their 70s or 80s, due to their limited lifespan from COPD, DM, malignancy, etc., and their expressed wishes to continue tobacco, we keep our admonitions to a minimum. We accept our patient has become learned enough through life to make their own decisions and accept whatever […]
Do you have a stack of journals piling up on your desk, beside your bed or in your email inbox? In 1950, medical knowledge was estimated to double every 50 years, but now the doubling time is every few months. At this rate, it is impossible to keep up with the literature, but a group […]
Fill in the Blanks: Q: “The diagnosis of type 2 MI is associated with a _____ prognosis. ___% of patients will live five years after their diagnosis.” The answer is a) POOR and b) a staggering 40%. I did not know that. However, what I am aware of is the ambiguity around Type 2 MIs and […]
Leave A Comment